初发甲状腺功能异常患者血清甲状腺激素与Cr、Cys C的相关性

doi:10.3969/j.issn.1673-8640.2020.07.014

摘要/Abstract

摘要：

目的探讨初发甲状腺功能异常患者血清甲状腺激素与肌酐（Cr）、胱抑素C（Cys C）的相关性。方法选取甲状腺功能异常患者368例[亚临床甲状腺功能减退（简称亚临床甲减）108例、甲状腺功能减退（简称甲减）59例、亚临床甲状腺功能亢进（简称亚临床甲亢）102例、甲状腺功能亢进（简称甲亢）99例],以270名体检健康者作为正常对照组,检测所有对象血清促甲状腺激素（TSH）、游离三碘甲状腺原氨酸（FT₃）、游离甲状腺素（FT₄）、Cr和Cys C水平。采用Spearman相关分析评估各项目之间的相关性。结果甲亢组血清Cr水平、亚临床甲减组和甲减组血清Cys C水平均低于正常对照组（P<0.01、P<0.05、P<0.01）,甲亢组血清Cys C水平高于正常对照组（P<0.01）。Cr与FT₃、FT₄呈负相关（r值分别为-0.082、-0.119,P<0.05）,与TSH呈正相关（r=0.202,P<0.01）。Cys C与FT₃、FT₄呈正相关（r值分别为0.281、0.197,P<0.01）,与TSH呈负相关（r=-0.214,P<0.01）。结论甲状腺功能异常患者,尤其是甲亢患者的甲状腺激素对血清Cys C和Cr水平有明显影响。

关键词: 肌酐, 胱抑素C, 肾功能, 甲状腺功能异常

Abstract:

Objective To investigate the correlation between serum thyroid hormones and creatinine（Cr） and cystatin C（Cys C） in patients with initial thyroid dysfunction. Methods A total of 368 patients with thyroid dysfunction,including 108 cases of subclinical hypothyroidism,59 cases of hypothyroidism,102 cases of subclinical hyperthyroidism and 99 cases of hyperthyroidism,were enrolled. Totally,270 healthy subjects were enrolled as healthy control group. Serum thyroid-stimulating hormone（TSH）,free triiodothyronine（FT₃）,free thyroxine（FT₄）,Cr and Cys C levels were determined. Spearman correlation analysis was used to correlation evaluation. Results The level of serum Cr in hyperthyroidism group and serum Cys C levels in subclinical hypothyroidism group and hypothyroidism group were lower than those in healthy control group（P<0.01,P<0.05,P<0.01）. Serum Cys C level in hyperthyroidism group was higher than that in healthy control group（P<0.01）. Cr was negatively correlated with FT₃ and FT₄（r=-0.082 and -0.119,P<0.05）,and it was positively correlated with TSH（r=0.202,P<0.01）. Cys C was positively correlated with FT₃ and FT₄（r=0.281 and 0.197,P<0.01）,and it was negatively correlated with TSH（r=-0.214,P<0.01）. Conclusions Thyroid hormones in patients with thyroid dysfunction,especially in patients with hyperthyroidism,have effects on serum Cys C and Cr levels.

Key words: Creatinine, Cystatin C, Kidney function, Thyroid dysfunction

中图分类号:

R446.1

张科, 童书韬, 张德太. 初发甲状腺功能异常患者血清甲状腺激素与Cr、Cys C的相关性[J]. 检验医学, 2020, 35(7): 691-694.

ZHANG Ke, TONG Shutao, ZHANG Detai. Correlation between serum thyroid hormones and Cr and Cys C in patients with initial thyroid dysfunction[J]. Laboratory Medicine, 2020, 35(7): 691-694.

图/表 2

参考文献 13

[1]	FILLER G,BÖKENKAMP A,HOFMANN W,et al. Cystatin C as a marker of GFR-history,indications,and future research[J]. Clin Biochem,2005,38(1):1-8.
[2]	MONTENEGRO J,GONZÁLEZ O,SARACHO R,et al. Changes in renal function in primary hypothyroidism[J]. Am J Kidney Dis,1996,27(2):195-198.
[3]	WILLIAMS T L,DILLON H,ELLIOTT J,et al.Serum cystatin C concentrations in cats with hyperthyroidism and chronic kidney disease[J]. J Vet Intern Med,2016,30(4):1083-1089.
[4]	GHYS L F,PAEPE D,DUCHATEAU L,et al.Biological validation of feline serum cystatin C:the effect of breed,age and sex and establishment of a reference interval[J]. Vet J,2015,204(2):168-173.
[5]	OZDEN T A,TEKEREK H,BAS F,et al.Effect of hypo-and euthyroid status on serum cystatin C levels[J]. J Clin Res Pediatr Endocrinol,2010,2(4):155-158.
[6]	HORIO M,IMAI E,YASUDA Y,et al.GFR estimation using standardized serum cystatin C in Japan[J]. Am J Kidney Dis,2013,61(2):197-203.
[7]	SIMEONI M,CERANTONIO A,PASTORE I,et al.The correct renal function evaluation in patient with thyroid dysfunction[J]. J Endocrinol Invest,2016,39(5):495-507.
[8]	VERHELST J,BERWAERTS J,MARESCAU B,et al.Serum creatine,creatinine,and other guanidino compounds in patients with thyroid dysfunction[J]. Metabolism,1997,46(9):1063-1067.
[9]	GHYS L F,MEYER E,PAEPE D,et al.Analytical validation of a human particle-enhanced nephelometric assay for cystatin C measurement in feline serum and urine[J]. Vet Clin Pathol,2014,43(2):226-234.
[10]	SCHMID C,GHIRLANDA-KELLER C,ZWIMPFER C,et al.Triiodothyronine stimulates cystatin C production in bone cells[J]. Biochem Biophys Res Commun,2012,419(2):425-430.
[11]	KOTAJIMA N,YANAGAWA Y,AOKI T,et al.Influence of thyroid hormones and transforming growth factor-β1 on cystatin C concentrations[J]. J Int Med Res,2010,38(4):1365-1373.
[12]	KHATIWADA S,RAJENDRA K C,GAUTAM S,et al.Thyroid dysfunction and dyslipidemia in chronic kidney disease patients[J]. BMC Endocr Disord,2015,15:65.
[13]	钱燕斐,徐佳音,曹蔚,等. 血清视黄醇结合蛋白与胱抑素C检测在儿童慢性肾病中的诊断意义[J]. 检验医学,2017,32(6):508-510.

组别	例数	Cr/（μmol/L）	Cys C/（mg/L）
正常对照组	270	67.40±14.03	0.89（0.79~0.99）
亚临床甲减组	108	70.11±21.10	0.85（0.73~0.98）^*
甲减组	59	71.12±17.59	0.82（0.71~0.91）^**
亚临床甲亢组	102	65.98±22.62	0.90（0.77~1.00）
甲亢组	99	56.33±15.89^**	0.99（0.84~1.24）^**

组别	例数	Cr/（μmol/L）	Cys C/（mg/L）
正常对照组	270	67.40±14.03	0.89（0.79~0.99）
亚临床甲减组	108	70.11±21.10	0.85（0.73~0.98）^*
甲减组	59	71.12±17.59	0.82（0.71~0.91）^**
亚临床甲亢组	102	65.98±22.62	0.90（0.77~1.00）
甲亢组	99	56.33±15.89^**	0.99（0.84~1.24）^**

[1]	俞琪, 王砚春, 郭林, 卢仁泉. 粒子放疗对前列腺癌患者骨髓、肝和肾功能的影响[J]. 检验医学, 2023, 38(5): 430-434.
[2]	李莲, 黄晓玲, 姚娟. 高浓度肌酸致血清肌酐酶法检测结果假性升高病例分析[J]. 检验医学, 2023, 38(5): 497-501.
[3]	顾刚, 欧维正, 陶铜芳, 董江义. 改良肌氨酸氧化酶法肌酐试剂抗高IgM干扰分析[J]. 检验医学, 2023, 38(3): 294-296.
[4]	戴健敏, 陈诺, 魏坚. 慢性肾脏病不同阶段患者血清ProGRP、NSE、CYFRA21-1水平的变化[J]. 检验医学, 2022, 37(9): 811-814.
[5]	张水检, 周琰, 邵文琦, 张春燕, 潘柏申, 王蓓丽, 郭玮. 半定量干化学法检测尿白蛋白/肌酐比值的临床应用价值[J]. 检验医学, 2022, 37(5): 463-465.
[6]	黄思聪, 石永杰, 嘉红云. FK506、肾功能指标及单个核细胞计数判断肾移植患者尿BKV DNA阳性的价值[J]. 检验医学, 2021, 36(8): 837-842.
[7]	刘非, 胡炎伟. 分析前因素对血清肾功能检测项目测定结果的影响[J]. 检验医学, 2021, 36(4): 369-373.
[8]	邵文琦, 于正麟, 吴群, 张春燕, 王蓓丽, 潘柏申, 郭玮. 盐酸利多卡因致血清干化学肌酐定量结果异常1例报道[J]. 检验医学, 2021, 36(4): 381-383.
[9]	张卫威, 景蓉蓉, 季伙燕, 王建新, 王峰, 王惠民. 同位素稀释质谱法测定血清肌酐浓度的不确定度评定[J]. 检验医学, 2021, 36(3): 263-269.
[10]	朱庆华, 王伟伟, 邹广慧, 董志武. 血清NGAL和Cys C联合检测在诊断2型糖尿病早期肾损伤中的价值[J]. 检验医学, 2021, 36(3): 281-284.
[11]	徐文俊, 李甲勇, 李会丹. 不同eGFR公式与ACR联合应用在肾功能损伤高危人群中的临床价值[J]. 检验医学, 2021, 36(1): 13-19.
[12]	李立和, 孙国忠, 张超. 内源性尿素对化学发光法检测TgAb、TPOAb和TSH的干扰研究[J]. 检验医学, 2020, 35(7): 682-685.
[13]	任丽, 侯岱, 申浩, 张时民. 尿液中检出阿昔洛韦药物结晶1例及文献复习[J]. 检验医学, 2020, 35(11): 1112-1114.
[14]	郑思涵, 刘明聪, 栾亮, 刘静, 田笑, 刘亚萌, 万楠. 武汉地区1 743例COVID-19患者生化常规项目分析[J]. 检验医学, 2020, 35(11): 1130-1135.
[15]	陈俊. Cys C、α-klotho蛋白、sICAM-1与糖尿病肾病的相关性[J]. 检验医学, 2020, 35(10): 1032-1035.